<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00218153</url>
  </required_header>
  <id_info>
    <org_study_id>NIDA-13334-1</org_study_id>
    <secondary_id>P50-13334-1</secondary_id>
    <nct_id>NCT00218153</nct_id>
  </id_info>
  <brief_title>Naltrexone Augmentation of Nicotine Patch Therapy - 1</brief_title>
  <official_title>Naltrexone Augmentation of Nicotine Patch Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute on Drug Abuse (NIDA)</source>
  <brief_summary>
    <textblock>
      Naltrexone Augmentation of Nicotine Patch Therapy&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This double blind placebo controlled study is designed to determine whether naltrexone can be&#xD;
      used to help reduce cigarette use and craving for cigarettes. Eligible participants will&#xD;
      receive 21mg transdermal nicotine as an outpatient. In addition, participants will receive&#xD;
      one of three doses of naltrexone (25,50 or 100mg) or a placebo and brief counseling over the&#xD;
      course of six weeks with follow-up appointments three, six, and twelve months after the&#xD;
      beginning of treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2000</start_date>
  <completion_date>April 2004</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <enrollment>200</enrollment>
  <condition>Tobacco Use Disorder</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naltrexone</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 18 and older&#xD;
&#xD;
          2. Willingness and ability to give written consent&#xD;
&#xD;
          3. Smoking 20 cigarettes per day for at least 1 year&#xD;
&#xD;
          4. At least one prior attempt to stop smoking&#xD;
&#xD;
          5. Baseline expired carbon-monoxide level of at least 10 ppm&#xD;
&#xD;
          6. Weigh at least 100 lbs.&#xD;
&#xD;
          7. English speaking&#xD;
&#xD;
          8. One person per household&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnant or nursing women or women who do not use a reliable form of birth control&#xD;
&#xD;
          2. Unstable cardiac disease&#xD;
&#xD;
          3. History of dermatoses&#xD;
&#xD;
          4. Current alcohol dependence&#xD;
&#xD;
          5. Current use of opiates&#xD;
&#xD;
          6. A urine drug screen that is positive for opiates&#xD;
&#xD;
          7. Serious current neurologic, psychiatric or medical illness&#xD;
&#xD;
          8. Chronic pain conditions necessitating opioid treatment&#xD;
&#xD;
          9. Evidence of significant hepatocellular injury as evidence by SGOT or SGPT &gt;3 x normal&#xD;
             or elevated bilirubin&#xD;
&#xD;
         10. Current use of smokeless tobacco, pipes, cigars, nicotine gum or nicotine patch&#xD;
&#xD;
         11. Patients requiring concomitant therapy with any psychotropic drug or on any drug with&#xD;
             a psychotropic component&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephanie O'Malley, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Substance Abuse Treatment Unit</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Substance Abuse Treatment Unit</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06519</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA Connecticut Health Care System</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06519</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2005</verification_date>
  <study_first_submitted>September 16, 2005</study_first_submitted>
  <study_first_submitted_qc>September 16, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2005</study_first_posted>
  <last_update_submitted>January 11, 2017</last_update_submitted>
  <last_update_submitted_qc>January 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 12, 2017</last_update_posted>
  <keyword>nicotine dependence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tobacco Use Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naltrexone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

